DOV KADMON to Genetic Therapy
This is a "connection" page, showing publications DOV KADMON has written about Genetic Therapy.
Connection Strength
1.075
-
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82.
Score: 0.222
-
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
Score: 0.151
-
In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther. 2001 May; 1(3):481-95.
Score: 0.108
-
Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol. 2000 Jul; 31(7):866-70.
Score: 0.102
-
Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene. World J Urol. 2000 Apr; 18(2):125-9.
Score: 0.100
-
Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis. 2009; 12(3):301-9.
Score: 0.046
-
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer. 2007 Dec 15; 110(12):2628-39.
Score: 0.043
-
Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat. 2006 Feb; 5(1):23-36.
Score: 0.038
-
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71.
Score: 0.033
-
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
Score: 0.033
-
Gene therapy for prostate cancer. Expert Rev Anticancer Ther. 2002 Jun; 2(3):309-21.
Score: 0.029
-
Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5):458-66.
Score: 0.028
-
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):605-13.
Score: 0.028
-
Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67.
Score: 0.028
-
In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer. Mol Ther. 2001 Apr; 3(4):500-6.
Score: 0.027
-
Gene therapy for prostate cancer. Urology. 2001 Jan; 57(1):8-16.
Score: 0.026
-
Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol. 2000 Jun; 163(6):1747-50.
Score: 0.025
-
Therapeutic targets for metastatic prostate cancer. Curr Drug Targets. 2003 Apr; 4(3):251-61.
Score: 0.008